NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing (NGS) in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on NGS in oncology.
- Mark Agulnik, MD, and Mrinal M. Guckavan, MD, among others, highlight the benefits of NGS in treatment planning.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Other notable experts such as Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Firooz, MD, contribute to the discussion on NGS.
Author's summary: NGS improves biomarker testing.More News
- Why we must work together for a balanced drinking culture
- SJHN Daily: Celebrini Named NHL First Star of the Week
- 400,000 Coloradans have cast votes so far
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- University of Central Arkansas establishes NWA advisory council - Talk Business & Politics
- Frogs help Fred Hutch find the shape of small things
- Importing beef is not the solution | GABEL
- Newsom considering 2028 run, calls Trump an ‘invasive species’
- AI Mahabharat On Star Plus: Will It Revolutionise Indian TV Content?